A focused report on IFN-1 targeted therapies for lupus erythematosus

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Systemic Lupus Erythematosus (SLE) presents complex, heterogeneous clinical manifestations and unpredictable disease flares.
• Existing treatments, including anifrolumab, voclosporin, and belimumab, complement but do not fully replace traditional therapies, indicating an unmet need for novel medications.
• Elevated levels of type I interferon (IFN-I) are a hallmark of SLE, making the IFN-I pathway a key target for therapeutic intervention.

Purpose of the Study:

• To review clinical trial outcomes of emerging medications targeting cytokine activity in SLE.
• To evaluate the efficacy and mechanisms of action of novel SLE therapeutics, particularly those focused on the IFN-I pathway.

Main Methods:

• Summarization of clinical trial data for four investigational drugs: Litifilimab, Daxdilimab, Anifrolumab, and Deucravacitinib.
• Analysis of the molecular targets and mechanisms by which these drugs modulate the IFN-I pathway.

Main Results:

• Litifilimab demonstrated a 7-point reduction in CLASI-A in Phase II trials.
• Anifrolumab showed reduced SLE activity in both Phase II and III trials.
• Deucravacitinib decreased disease activity across multiple measures in its Phase II trial, while Daxdilimab's Phase II trial was unsuccessful.

Conclusions:

• Targeting the IFN-I pathway represents a promising therapeutic strategy for managing Systemic Lupus Erythematosus.
• Litifilimab, Anifrolumab, and Deucravacitinib exhibit potential for treating SLE by modulating IFN-I signaling, though further investigation is warranted.